Advertisement

Clinical & Experimental Metastasis

, Volume 32, Issue 5, pp 457–465 | Cite as

Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases

  • Lydia G. M. van der GeestEmail author
  • Jorine’t Lam-Boer
  • Miriam Koopman
  • Cees Verhoef
  • Marloes A. G. Elferink
  • Johannes H. W. de Wilt
Research Paper

Abstract

The aim of this study was to determine trends in incidence, treatment and survival of colorectal cancer (CRC) patients with synchronous metastases (Stage IV) in the Netherlands. This nationwide population-based study included 160,278 patients diagnosed with CRC between 1996 and 2011. We evaluated changes in stage distribution, location of synchronous metastases and treatment in four consecutive periods, using Chi square tests for trend. Median survival in months was determined, using Kaplan–Meier analysis. The proportion of Stage IV CRC patients (n = 33,421) increased from 19 % (1996–1999) to 23 % (2008–2011, p < 0.001). This was predominantly due to a major increase in the incidence of lung metastases (1.7–5.0 % of all CRC patients). During the study period, the primary tumor was resected less often in Stage IV patients (65–46 %) and the use of systemic treatment has increased (29–60 %). Also an increase in metastasectomy was found in patients with one metastatic site, especially in patients with liver-only disease (5–18 %, p < 0.001). Median survival of all Stage IV CRC patients increased from 7 to 12 months. Especially in patients with metastases confined to the liver or lungs this improvement in survival was apparent (9–16 and 12–24 months respectively, both p < 0.001). In the last two decades, more lung metastases were detected and an increasing proportion of Stage IV CRC patients was treated with systemic therapy and/or metastasectomy. Survival of patients has significantly improved. However, the prognosis of Stage IV patients becomes increasingly diverse.

Keywords

Epidemiology Colorectal cancer Synchronous metastases Treatment Survival 

Notes

Conflict of interest

The submitted material has not been published and is not under consideration for publication elsewhere. We declare there are no conflicts of interest. The manuscript has been seen and approved by all authors.

References

  1. 1.
    Netherlands Cancer R. Dutch Cancer Figures. 2013Google Scholar
  2. 2.
    van der Pool AE, Damhuis RA, Ijzermans JN et al (2012) Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 14:56–61PubMedCrossRefGoogle Scholar
  3. 3.
    Elferink MA, van Steenbergen LN, Krijnen P et al (2010) Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989–2006. Eur J Cancer 46:1421–1429 (Oxford, England : 1990)PubMedCrossRefGoogle Scholar
  4. 4.
    van Steenbergen LN, Elferink MA, Krijnen P et al (2010) Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989–2006. Ann Oncol 21:2206–2212PubMedCrossRefGoogle Scholar
  5. 5.
    Kanas GP, Taylor A, Primrose JN et al (2012) Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 4:283–301PubMedCentralPubMedGoogle Scholar
  6. 6.
    Hackl C, Gerken M, Loss M et al (2011) A population-based analysis on the rate and surgical management of colorectal liver metastases in southern Germany. Int J Colorectal Dis 26:1475–1481PubMedCrossRefGoogle Scholar
  7. 7.
    Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Gonzalez M, Poncet A, Combescure C et al (2013) Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 20:572–579PubMedCrossRefGoogle Scholar
  9. 9.
    de Cuba EM, Kwakman R, Knol DL et al (2013) Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev 39:321–327PubMedCrossRefGoogle Scholar
  10. 10.
    de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMedGoogle Scholar
  11. 11.
    Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914PubMedCrossRefGoogle Scholar
  12. 12.
    Koopman M, Antonini NF, Douma J et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135–142PubMedCrossRefGoogle Scholar
  13. 13.
    Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  14. 14.
    Cirocchi R, Trastulli S, Abraha I et al (2012) Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. The Cochrane database of systematic reviews 8:CD008997Google Scholar
  15. 15.
    Verhoef C, de Wilt JH, Burger JW et al (2011) Surgery of the primary in stage IV colorectal cancer with unresectable metastases. Eur J Cancer 47(Suppl 3):S61–S66 (Oxford, England : 1990)PubMedCrossRefGoogle Scholar
  16. 16.
    Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology (ICD-O). World Health Organization, GenevaGoogle Scholar
  17. 17.
    Wittekind C, Greene FL, Hutter RVP et al (2004) TNM atlas. Springer, BerlinGoogle Scholar
  18. 18.
    Nagtegaal ID, Tot T, Jayne DG et al (2011) Lymph nodes, tumor deposits, and TNM: are we getting better? J Clin Oncol 29:2487–2492PubMedCrossRefGoogle Scholar
  19. 19.
    Parnaby CN, Bailey W, Balasingam A et al (2012) Pulmonary staging in colorectal cancer: a review. Colorectal Dis 14:660–670PubMedCrossRefGoogle Scholar
  20. 20.
    Bipat S, Niekel MC, Comans EF et al (2012) Imaging modalities for the staging of patients with colorectal cancer. Neth J Med 70:26–34PubMedGoogle Scholar
  21. 21.
    Mitry E, Guiu B, Cosconea S et al (2010) Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 59:1383–1388PubMedCrossRefGoogle Scholar
  22. 22.
    Wiering B, Vogel WV, Ruers TJ et al (2008) Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Dig Surg 25:413–420PubMedCrossRefGoogle Scholar
  23. 23.
    Mitry E, Rollot F, Jooste V et al (2013) Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies? Eur J Cancer 49:2919–2925 (Oxford, England : 1990)PubMedCrossRefGoogle Scholar
  24. 24.
    Damjanov N, Weiss J, Haller DG (2009) Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic disease. Oncologist 14:963–969PubMedCrossRefGoogle Scholar
  25. 25.
    Benoist S, Pautrat K, Mitry E et al (2005) Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 92:1155–1160PubMedCrossRefGoogle Scholar
  26. 26.
    Hu CY, Bailey CE, You YN et al (2015) Time trend analysis of primary tumor resection for stage iv colorectal cancer: less surgery, improved survival. JAMA Surg 150:245–251PubMedCrossRefGoogle Scholar
  27. 27.
    Scheer MG, Sloots CE, van der Wilt GJ et al (2008) Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19:1829–1835PubMedCrossRefGoogle Scholar
  28. 28.
    Vargas GM, Sheffield KM, Parmar AD et al (2014) Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J Gastrointest Surg 18:369–377PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Jones RP, Vauthey JN, Adam R et al (2012) Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 99:1263–1269PubMedCrossRefGoogle Scholar
  30. 30.
    Hattori N, Kanemitsu Y, Komori K et al (2013) Outcomes after hepatic and pulmonary metastasectomies compared with pulmonary metastasectomy alone in patients with colorectal cancer metastasis to liver and lungs. World J Surg 37:1315–1321PubMedCrossRefGoogle Scholar
  31. 31.
    Chua TC, Saxena A, Liauw W et al (2012) Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases–a systematic review. Eur J Cancer 48:1757–1765 (Oxford, England : 1990)PubMedCrossRefGoogle Scholar
  32. 32.
    Sorbye H, Cvancarova M, Qvortrup C et al (2013) Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 24:2354–2360PubMedCrossRefGoogle Scholar
  33. 33.
    Kornmann M, Staib L, Wiegel T et al (2013) Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer. Clin Colorectal Cancer 12:54–61PubMedCrossRefGoogle Scholar
  34. 34.
    Khattak MA, Martin HL, Beeke C et al (2012) Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 11:247–254PubMedCrossRefGoogle Scholar
  35. 35.
    Lemmens VE, Klaver YL, Verwaal VJ et al (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128:2717–2725PubMedCrossRefGoogle Scholar
  36. 36.
    Mol L, Koopman M, van Gils CW et al (2013) Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol 52:950–955PubMedCrossRefGoogle Scholar
  37. 37.
    Downs-Canner S, Bahar R, Reddy SK et al (2012) Indeterminate pulmonary nodules represent lung metastases in a significant portion of patients undergoing liver resection for malignancy. J Gastrointest Surg 16:2256–2259PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • Lydia G. M. van der Geest
    • 1
    Email author
  • Jorine’t Lam-Boer
    • 2
  • Miriam Koopman
    • 3
  • Cees Verhoef
    • 4
  • Marloes A. G. Elferink
    • 1
  • Johannes H. W. de Wilt
    • 2
  1. 1.Netherlands Comprehensive Cancer Organisation (IKNL)UtrechtThe Netherlands
  2. 2.Department of SurgeryRadboud University Medical CenterNijmegenThe Netherlands
  3. 3.Department of Medical OncologyUtrecht University Medical CenterUtrechtThe Netherlands
  4. 4.Department of SurgeryRotterdam University Medical CenterRotterdamThe Netherlands

Personalised recommendations